基于血液生物标志物的外周免疫评分及在非小细胞肺癌应用中的研究进展OACSTPCD
Research Progress of Peripheral Immune Score Based on Blood Biomarkers and Its Application in Non-small Cell Lung Cancer
肺癌是目前中国人群中发病率和死亡率最高的恶性肿瘤,美国癌症联合委员会(American Joint Committee on Cancer,AJCC)和国际抗癌联盟(International Union Against Cancer,UICC)制定的肿瘤淋巴结转移分类(tumor node metastasiss,TNM)分期是判断非小细胞肺癌(non-small cell lung cancer,NSCLC)分期的常用标准,但其在判断预后方面仍存在局限性.基于外周血生物标志物的免疫评分被证明在NSCLC患者中具有预测药物疗效和患者预后的能力,且具有取样方便、实时检测等优势,被广泛开发、验证,但临床上对外周免疫评分的应用尚未普及.因此,该文总结、质量评价6项外周免疫评分,并就外周免疫评分在NSCLC中的应用进行述评,以期总结目前外周免疫评分的价值和不足,为今后的研究和应用提供参考.
Lung cancer is the malignant tumor with the highest incidence and mortality among the Chinese.Tumor node metastasis(TNM)staging established by the American Joint Committee on Cancer(AJCC)and International Union Against Cancer(UICC)is a commonly used criterion,but it still has limitations in judging the prognosis of non-small cell lung cancer(NSCLC)patients.With the advantages of real-time and convenient sampling,the immune score based on peripheral blood biomarkers have the ability to predict prognosis and efficacy of NSCLC patients,which have been developed and validated in clinical studies.However,clinical impleruentation of peripheral immune scores is still not widely in NSCLC patients.Therefore,this study introduces and evaluates the 6 peripheral immune scores and reviews the reseach progress of them in the treatment of NSCLC.
田雪琪;宋佳俊;顾怿丰;吴冠锦;焦丽静;许玲
上海中医药大学附属岳阳中西医结合医院肿瘤一科,上海 200437上海中医药大学附属岳阳中西医结合医院肿瘤一科,上海 200437||上海中医药大学附属岳阳中西医结合医院中西医结合肿瘤转化研究所,上海 200437
临床医学
非小细胞肺癌外周免疫评分预测模型
non-small cell lung cancerperipheral immune scorepredictive model
《现代检验医学杂志》 2024 (001)
192-198 / 7
国家自然科学基金面上项目(82274595):基于巨噬细胞极化及Th1细胞串扰探讨肺平方延缓肺癌耐药机制;上海市科学技术委员会科技计划项目(20Y21902000):益气养阴法联合EGFR-TKI靶向治疗IV期肺癌优势人群的前瞻性研究;上海市科学技术委员会"科技创新行动计划"自然科学基金项目(22ZR1462400):益气养阴解毒方调控MMP2/PD-L1介导的免疫逃逸延缓EGFR-TKI耐药的分子机制.
评论